BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy  CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible...
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

The April deal between Arrakis and Roche started with dinner in Basel and closed over Zoom. In a podcast conversation with BioCentury, the architects of the deal, James Sabry and Michael Gilman, describe how the...
BC Innovations | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way. Build-to-buy deal structures...
BC Extra | Sep 26, 2018
Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
BC Week In Review | Dec 15, 2017
Company News

Federal Appeals Court rules that Biosimilars Act preempts state law

In a ruling issued in the case of Amgen Inc. v. Sandoz Inc. concerning biosimilars, the U.S. Court of Appeals for the Federal Circuit (CAFC) held that the federal Biologics Price Competition and Innovation Act...
BC Extra | Dec 14, 2017
Politics & Policy

Appeals court: Federal biosimilars act preempts state law

In a ruling issued in the case of Amgen Inc. v. Sandoz Inc. concerning biosimilars, the U.S. Court of Appeals for the Federal Circuit (CAFC) held that the federal Biologics Price Competition and Innovation Act...
BioCentury | Sep 22, 2017
Politics, Policy & Law

Conferred immunity in IPR

The outcome of Allergan plc ’s gambit to shield its Restasis cyclosporine patents from inter partes review could determine the fate of the IPR system and upset the balance of power between generic and brand...
BC Extra | Sep 15, 2017
Politics & Policy

U.S. government asserts biosimilars act preempts state law

On Monday, the U.S. government submitted an amicus brief to the U.S. Court of Appeals for the Federal Circuit (CAFC) in the case of Amgen Inc. v. Sandoz Inc. arguing that the federal Biologics Price...
BC Week In Review | Jun 16, 2017
Company News

SCOTUS shortens time to market for Novartis' biosimilar of Neupogen from Amgen

A unanimous ruling issued June 12 by the U.S. Supreme Court will shorten the timeline for biosimilars to reach the market by six months, and is likely to give the drugs' manufacturers flexibility to decline...
BC Extra | Jun 12, 2017
Politics & Policy

SCOTUS speeds biosimilars to market

A unanimous ruling issued Monday by the U.S. Supreme Court will shorten the timeline for biosimilars to reach the market by six months, and is likely to give the drugs' manufacturers flexibility to decline to...
Items per page:
1 - 10 of 59